Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Van Laar

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
Clinical Neuropharmacology|February 1, 1994
Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responsesD J Hofstee, C Neef, T van Laar, et al.
Archives of Neurology|May 1, 1992
Intranasal apomorphine in parkinsonian on-off fluctuationsT van Laar, E N Jansen, A W Essink, et al.
Psychiatry Research|August 26, 2019
Visual hallucinations in psychosisM M van Ommen, T van Laar, F W Cornelissen, et al.
Molecular Carcinogenesis|June 29, 2001
Induction of the SAPK activator MIG-6 by the alkylating agent methyl methanesulfonateT van Laar, T Schouten, A J van der Eb, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1995
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositoriesT van Laar, E N Jansen, C Neef, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1996
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's diseaseT van Laar, C Neef, M Danhof, et al.
Clinical Neuropharmacology|October 23, 1997
Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and thresholdJ J van Hilten, E A Wagemans, S F Ghafoerkhan, et al.
British Journal of Clinical Pharmacology|April 22, 2016
A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticityH W Heetla, J H Proost, B H Molmans, et al.
Cytometry|September 1, 1996
Temperature-sensitive mutant p53 (ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cellsT van Laar, R Schouten, A G Jochemsen, et al.
Journal of Virology|September 1, 1993
Large E1B proteins of adenovirus types 5 and 12 have different effects on p53 and distinct roles in cell transformationS J van den Heuvel, T van Laar, I The, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
Clinical Neuropharmacology|February 1, 1994
Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responsesD J Hofstee, C Neef, T van Laar, et al.
Archives of Neurology|May 1, 1992
Intranasal apomorphine in parkinsonian on-off fluctuationsT van Laar, E N Jansen, A W Essink, et al.
Psychiatry Research|August 26, 2019
Visual hallucinations in psychosisM M van Ommen, T van Laar, F W Cornelissen, et al.
Molecular Carcinogenesis|June 29, 2001
Induction of the SAPK activator MIG-6 by the alkylating agent methyl methanesulfonateT van Laar, T Schouten, A J van der Eb, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 1, 1995
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositoriesT van Laar, E N Jansen, C Neef, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1996
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's diseaseT van Laar, C Neef, M Danhof, et al.
Clinical Neuropharmacology|October 23, 1997
Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and thresholdJ J van Hilten, E A Wagemans, S F Ghafoerkhan, et al.
British Journal of Clinical Pharmacology|April 22, 2016
A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticityH W Heetla, J H Proost, B H Molmans, et al.
Cytometry|September 1, 1996
Temperature-sensitive mutant p53 (ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cellsT van Laar, R Schouten, A G Jochemsen, et al.
Journal of Virology|September 1, 1993
Large E1B proteins of adenovirus types 5 and 12 have different effects on p53 and distinct roles in cell transformationS J van den Heuvel, T van Laar, I The, et al.
Pageof 7